The PD-1/PD-L1 axis is a key target in cancer immunotherapy [5, 6], with increasing evidence suggesting that PD-L1 expression on tumor cells can serve as a critical biomarker for predicting the efficacy of anti-PD-1/PD-L1 therapies [13, 14]. This evidence concerns the gene CD274 and neoplasm.